AbbVie Inc. (NYSE:ABBV) is included among the 10 Best Large Cap Dividend Growth Stocks to Invest in. On April 30, Bank of ...

AbbVie Inc. raised its full-year profit forecast after quarterly results beat estimates, a sign of confidence amid growing ...

AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira and Imbruvica declines.

AbbVie (ABBV) shares climbed roughly 2% in premarket trading Thursday after the pharma giant raised its full-year earnings outlook on the back of a strong first-quarter revenue beat, and the results ...

AbbVie Inc. (NYSE:ABBV) is a global biopharma company built around research and a fairly broad mix of treatments.

Q1 2026 earnings call recap: guidance raise, $15B revenue, Skyrizi/Rinvoq outlook, pipeline catalysts & risks—read key takeaways now.

AbbVie (ABBV) stock climbed 2.5% premarket after Q1 earnings and revenue topped forecasts. The company also lifted its ...

Gov. Josh Stein announced AbbVie Inc., one of the world's largest biopharmaceutical companies, is coming to Durham.

AbbVie Inc. shares are down during Friday’s premarket session following a Complete Response Letter (CRL) from the FDA ...

(ABBV) on Wednesday reported first-quarter earnings of $695 million. The North Chicago, Illinois-based company said it had net income of 39 cents per share. Earnings, adjusted for non-recurring costs ...

AbbVie Inc., enticed in part by a $50.8 million incentive package, has chosen North Carolina for construction of a $1.4 ...

On April 20, 2026, Canaccord initiated coverage of AbbVie Inc. (NYSE:ABBV) with a Buy rating and a $262 price target on the ...